Source-grounded facts extracted from MIRA PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Andriy Mushak was appointed as fractional Chief Financial Officer at MIRA PHARMACEUTICALS, INC..
“On June 2, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).”
Alan Weichselbaum resigned as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..
“Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”).”
MIRA PHARMACEUTICALS, INC. amended Amended and Restated Exclusive License Agreement with MIRALOGX LLC (effective 2026-06-03).
“On June 3, 2026, MIRA Pharmaceuticals, Inc. (the "Company") entered into an Amended and Restated Exclusive License Agreement (the "License Agreement") with MIRALOGX LLC ("Miralogx").”
MIRA PHARMACEUTICALS, INC. amended Amendment No. 1 to Exclusive License Agreement with MIRALOGX LLC valued at Expanded exclusive licensed territory from US, Canada, Mexico to all countries with patent rights; e (effective 2026-05-21).
“On May 21, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Exclusive License Agreement, effective November 15, 2023, by and between the Company and MIRALOGX LLC.”
MIRA PHARMACEUTICALS, INC. completed an acquisition involving SKNY Pharmaceuticals, Inc. for restricted shares of the Company’s common stock (closed 2025-09-29).
“On September 29, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) completed its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”) pursuant to the previously announced merger agreement (the “Merger Agreement”).”
Alan Weichselbaum was appointed as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..
“Effective May 15, 2025, the Company appointed Alan Weichselbaum as the Chief Financial Officer of the Company.”
Michelle Yanez resigned as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..
“Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of MIRA Pharmaceuticals, Inc. (the “Company”), effective on that date.”
MIRA PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 8, 2025, MIRA Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff indicating that, based on the Company’s stockholders’ equity of $2,199,750 as of December 31, 2024, the Company does not currently meet the minimum stockholders’ equity requirement of $2.5 million as set forth under Nasdaq Listing Rule 5550(b)(1). Importantly, this notice does not affect the Company’s listing status or the trading of its common stock, which will continue uninterrupted on the Nasdaq Capital Market under the ticker symbol “MIRA.” In accordance with Nasdaq proc”
MIRA PHARMACEUTICALS, INC. engaged Salberg & Company P.A. as its auditor.
“On December 18 th , 2024, the Company engaged Salberg & Company P.A. (“Salberg”) as its new independent registered public accountant for the fiscal year ending December 31, 2024.”
Cherry Bekaert LLP resigned as auditor of MIRA PHARMACEUTICALS, INC..
“By letter dated December 16, 2024, Cherry Bekaert LLP (“Cherry Bekaert”) notified the Audit Committee of the Board of Directors (the “Audit Committee”) of MIRA Pharmaceuticals, Inc’s (the “Company”) of its resignation as the Company’s independent registered public accounting firm.”
Ned MacPherson was appointed as Director at MIRA PHARMACEUTICALS, INC..
“On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above”
Denil N. Shekhat was appointed as Director at MIRA PHARMACEUTICALS, INC..
“On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above”
Matthew P. Del Giudice was appointed as Director at MIRA PHARMACEUTICALS, INC..
“On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above”
Erez Aminov was appointed as Chairman of the Board at MIRA PHARMACEUTICALS, INC..
“On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above”
Chris Chapman resigned as Executive Chairman at MIRA PHARMACEUTICALS, INC..
“Also on March 9, 2024, Dr. Chris Chapman notified the Board and senior Company management of his resignation both as Executive Chairman and as an employee of the Company, effective immediately, citing his desire to focus his time on his role as Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc.”
Hugh McColl resigned as Director at MIRA PHARMACEUTICALS, INC..
“Ms. Talhia Tuck, Mr. Brad Kroenig and Mr. Hugh McColl, each voluntarily resigned from the Board, effective immediately.”
Brad Kroenig resigned as Director at MIRA PHARMACEUTICALS, INC..
“Ms. Talhia Tuck, Mr. Brad Kroenig and Mr. Hugh McColl, each voluntarily resigned from the Board, effective immediately.”
Talhia Tuck resigned as Director at MIRA PHARMACEUTICALS, INC..
“Ms. Talhia Tuck, Mr. Brad Kroenig and Mr. Hugh McColl, each voluntarily resigned from the Board, effective immediately.”
Christos Nicholoudis resigned as Director and part-time General Counsel at MIRA PHARMACEUTICALS, INC..
“On January 15, 2024, Christos Nicholoudis, Esq. resigned from the Board of Directors of the Company and as part-time General Counsel of the Company.”
Brian Daly resigned as Director at MIRA PHARMACEUTICALS, INC..
“on December 1, 2023, Brian Daly resigned from the Board of Directors of the Company.”
MIRA PHARMACEUTICALS, INC. incurred loan of up to $3.0 million with MIRALOGX at annual fixed rate of 8% maturing November 15, 2023.
“On November 15, 2023, the Company entered into a Promissory Note and Loan Agreement (the "Loan Agreement") with MIRALOGX. Pursuant to the Loan Agreement, the Company may borrow up to $3.0 million from MIRALOGX to fund the development of licensed products under the License Agreement (the "Loan").”
MIRA PHARMACEUTICALS, INC. entered into Promissory Note and Loan Agreement with MIRALOGX, LLC valued at Up to $3.0 million borrowing capacity; interest at 8% per annum; one-year term; repayment due Novemb (effective 2023-11-15).
“On November 15, 2023, the Company entered into a Promissory Note and Loan Agreement (the “Loan Agreement”) with MIRALOGX. Pursuant to the Loan Agreement, the Company may borrow up to $3.0 million from MIRALOGX to fund the development of licensed products under the License Agreement (the “Loan”).”
MIRA PHARMACEUTICALS, INC. entered into Exclusive License Agreement with MIRALOGX, LLC valued at $100,000 upfront payment plus quarterly royalties of 8% of net sales and 8% of other revenue; issuan (effective 2023-11-15).
“On November 15, 2023 (the “Effective Date”), MIRA Pharmaceuticals, Inc. (the “Company”) and MIRALOGX, LLC, a Florida limited liability company (“MIRALOGX”), entered into an exclusive license agreement (the “License Agreement”) to develop and commercialize a drug product containing 2-(2- chlorophenyl)-2-(methylamino) cyclopentan-1-one (sometimes referred to by the Parties as “M209” or “KETAMIR-2”) (“the Product”) as an active agent in North America.”
Michael Jerman was appointed as Director at MIRA PHARMACEUTICALS, INC..
“On November 14, 2023, the Board of Directors of the Company increased the number of directors on the Board from 7 directors to 8 directors and unanimously approved the election and appointment of Mr. Michael Jerman to the Board.”
David Vorhoff resigned as Director at MIRA PHARMACEUTICALS, INC..
“Also, on October 19, 2023, David Vorhoff, resigned from the Board of Directors of the Company.”
Brian Daly was appointed as Director at MIRA PHARMACEUTICALS, INC..
“On October 25, 2023, the Board of Directors (the “Board”) of MIRA Pharmaceuticals, Inc. (the “Company”) unanimously approved the election and appointment of Mr. Brian Daly to the Board.”
MIRA PHARMACEUTICALS, INC. entered into Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC (effective 2023-08-02).
“On August 2, 2023, MIRA Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC (“Kingswood”) on behalf of itself and as representative of the underwriters named therein (the “Underwriting Agreement”), pursuant to which the Company issued and sold, in an underwritten public offering (the “Public Offering”), 1,275,000 shares of common stock, $0.0001 par value per share (“Common Stock”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.